Skip to main content
OpenTrials

Clinical trial condition

Urothelial Carcinoma

Explore clinical trials studying Urothelial Carcinoma. Study availability and eligibility vary by location and protocol.

243 public trials 72 recruiting studies
Refine in advanced search Browse all conditions

Urothelial Carcinoma trial results

Completed

Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011)

NCT03898180

Conditions
Carcinoma, Carcinoma, Transitional Cell, Neoplasms, +4 more
Locations
  • Banner MD Anderson Cancer Center ( Site 0016) Gilbert, Arizona, United States
  • Community Cancer Institute ( Site 0777) Clovis, California, United States
  • University of California Irvine Medical Center ( Site 0078) Orange, California, United States
  • John Wayne Cancer Institute ( Site 0017) Santa Monica, California, United States
View all 194 locations
View Trial Details
Completed

MAGE-A10ᶜ⁷⁹⁶T for Urothelial Cancer, Melanoma or Head and Neck Cancers

NCT02989064

Conditions
Bladder Urothelial Carcinoma, Carcinoma, Carcinoma, Transitional Cell, +20 more
Locations
  • Massachusetts General Hospital Boston, Massachusetts, United States
  • Washington University - School of Medicine St Louis, Missouri, United States
  • Roswell Park Cancer Institute Buffalo, New York, United States
  • Ohio State University Wexner Medical Center Columbus, Ohio, United States
View Trial Details
Completed

Evolution of Proteomic Profiles of Intestinal Microbiota in Patients With Locally Advanced or Metastatic Urothelial Carcinomas

NCT04566029

Conditions
Carcinoma, Carcinoma, Transitional Cell, Neoplasms, +3 more
Locations
  • ICM parc euromedecine Montpellier, Hérault, France
  • Hopital Tenon ( Paris) Paris, Paris Cx 20, France
  • Institut Sainte Cancerologie Lucien Neuwirth Avignon, Saint Priest En Jarez, France
  • ICO-Site Paul Papin Angers, France
View Trial Details
Completed

Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors

NCT04344795

Conditions
Bronchial Neoplasms, Carcinoma, Carcinoma, Bronchogenic, +41 more
Locations
  • University of Colorado Aurora, Colorado, United States
  • Sidney Kimmel Cancer Center, Johns Hopkins School of Medicine Baltimore, Maryland, United States
  • Baystate Gynecologic Oncology Springfield, Massachusetts, United States
  • University of Michigan Rogel Cancer Center Ann Arbor, Michigan, United States
View Trial Details
Completed

Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer

NCT02475213

Conditions
Bronchial Neoplasms, Carcinoma, Carcinoma, Bronchogenic, +24 more
Locations
  • Mayo Clinic - AZ Scottsdale, Arizona, United States
  • Christiana Care Health Services, Inc. Newark, Delaware, United States
  • Mayo Clinic - FL Jacksonville, Florida, United States
  • Moffitt Cancer Center Tampa, Florida, United States
View all 20 locations
View Trial Details
Completed

Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors

NCT05585034

Conditions
Adenocarcinoma, Adnexal Diseases, Breast Diseases, +58 more
Locations
  • UCLA Hematology/Oncology Los Angeles, California, United States
  • Sarah Cannon Research Institute at HealthONE Denver, Colorado, United States
  • Florida Cancer Specialists Sarasota, Florida, United States
  • Winship Cancer Institute, Emory University Atlanta, Georgia, United States
View Trial Details

Related conditions